阿卡波糖治疗2型糖尿病及对血清炎性因子、抑胃肽、胰升血糖素样肽-1、空腹C肽的影响  

Effects of acarbose on type 2 diabetes mellitus and serum inflammatory factor,gastric inhibitory peptide,glucagon-like peptide-1 and fasting C-Peptide

作　　者：曹邓晗[1] 王志宏[1] CAO Denghan;WANG Zhihong(Department of Endocrinology,Zhengzhou First People’s Hospital,Zhengzhou,Henan 450004,China)

机构地区：[1]郑州市第一人民医院内分泌科,河南郑州450004

出　　处：《安徽医药》2021年第1期140-143,共4页Anhui Medical and Pharmaceutical Journal

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20191005)。

摘　　要：目的研究阿卡波糖治疗2型糖尿病(T2DM)及对血清炎性因子、抑胃肽(GIP)、胰升血糖素样肽-1(GLP-1)、空腹C肽(C-P)的影响。方法选择郑州市第一人民医院2014年7月至2018年6月收治的T2DM病人238例,按照随机数字表法分为阿卡波糖组与对照组,各119例。对照组给予甘精胰岛素治疗,阿卡波糖组在对照组基础上给予阿卡波糖治疗。观察两组血清空腹血糖(FPG)、餐后2 h血糖(2 h PG)及糖化血红蛋白(HbA1c)等指标治疗前后的差异,观察GIP、GLP-1、C-P、白介素-4(IL-4)、白介素-6(IL-6)、白介素-10(IL-10)等治疗前后水平的变化及两组间的不良反应。结果治疗后,阿卡波糖组FPG(5.07±0.52)mmol/L、2 h PG(7.58±0.77)mmol/L、HbA1c(6.07±0.62)%、GIP(1203.58±123.83)μg/L、IL-6(2.08±0.22)ng/L水平低于对照组(6.22±0.63)mmol/L、(9.71±0.99)mmol/L、(7.18±0.73)%、(1394.38±142.55)μg/L、(2.67±0.28)ng/L水平,IL-4(4.60±0.48)ng/L、IL-10(1.43±0.16)ng/L、GLP-1(26.85±2.67)pmol/L、C-P(2.48±0.26)μg/L水平均高于对照组(4.14±0.44)ng/L、(1.18±0.13)ng/L、(23.64±2.46)pmol/L、(2.21±0.24)μg/L(P<0.05)。阿卡波糖组不良反应发生率(10.92%)与对照组(5.04%)差异无统计学意义(P>0.05)。结论阿卡波糖可有效降低T2DM病人血糖水平,抑制炎症反应,改善GIP、GLP-1、C-P水平,安全可靠。Objective To study the effects of acarbose on Type 2 diabetes mellitus(T2DM)and serum Inflammatory factors,gastric inhibitory peptide(GIP),glucagon-like peptide-1(GLP-1)and fasting C-Peptide(C-P).Methods A total of 238 T2DM patients admitted to Zhengzhou First People’s Hospital from July 2014 to June 2018 were selected and divided into acarbose group and control group according to the random number table method,with 119 cases in each group.The control group was treated with insulin glargine and the Acarbose group was treated with acarbose on the basis of the control group.The differences of serum fasting plasma glucose(FPG),2 h postprandial glucose(2 hPG)and glycated hemoglobin(HbA1c)between the two groups before and after treatment were observed.The differences of serum GIP,GLP-1,C-P,IL-4,IL-6 and IL-10 between the two groups before and after treatment,and adverse reactions were observed.Results After treatment,the levels of FPG(5.07±0.52)mmol/L,2 h PG(7.58±0.77)mmol/L,HbA1c(6.07±0.62)%,GIP(1203.58±123.83)μg/L,IL-6(2.08±0.22)ng/L in the acarbose group were lower than those in the control group FPG(6.22±0.63)mmol/L,2 h PG(9.71±0.99)mmol/L,HbA1 c(7.18±0.73)%,GIP(1394.38±142.55)μg/L,IL-6(2.67±0.28)ng/L,and the levels of IL-4(4.60±0.48)ng/L,IL-10(1.43±0.16)ng/L,GLP-1(26.85±2.67)pmol/L,C-P(2.48±0.26)μg/L were all higher than those in the control group IL-4(4.14±0.44)ng/L,IL-10(1.18±0.13)ng/L,GLP-1(23.64±2.46)pmol/L,C-P(2.21±0.24)μg/L(P<0.05).There was no difference in the incidence of adverse reactions between the acarbose group(10.92%)and the control group(5.04%)(P>0.05).Conclusion Acarbose can effectively reduce the blood glucose level in patients with T2 DM,inhibit inflammatory response,promote recovery of GIP,GLP-1 and C-P,which is safe and reliable.

关 键 词：糖尿病 2型 阿卡波糖 炎性因子 抑胃肽 胰升血糖素样肽-1 C肽 

分 类 号：R587.1[医药卫生—内分泌]